

# Therapeutic recommendations in polycythemia vera based on Group protocols

Seminars in Hematology

23, 132-43

Citation Report

#	ARTICLE	IF	CITATIONS
2	Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. American Journal of Hematology, 1987, 25, 191-201.	2.0	60
3	Relative erythrocytosis. Journal of General Internal Medicine, 1987, 2, 128-130.	1.3	1
4	RISK FACTORS FOR THROMBOSIS IN POLYCYTHAEMIA VERA. British Journal of Haematology, 1988, 69, 422-423.	1.2	1
5	Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer, 1988, 61, 2487-2496.	2.0	185
7	Erythrocytapheresis. Klinische Wochenschrift, 1988, 66, 404-409.	0.6	22
8	Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis - features of significance for the diagnosis of primary (essential) thrombocythaemia. Virchows Archiv A, Pathological Anatomy and Histopathology, 1988, 413, 407-417.	1.4	42
9	Extramedullary haemopoietic tumours complicating polycythaemia vera.. Journal of Clinical Pathology, 1988, 41, 609-614.	1.0	14
10	Preleukemic Syndromes and Other Syndromes Predisposing to Leukemia. Pediatric Clinics of North America, 1988, 35, 853-871.	0.9	11
11	Polycythemia vera in an oral surgical patient A case report. Oral Surgery, Oral Medicine, and Oral Pathology, 1989, 67, 673-675.	0.6	6
12	Budd-chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klinische Wochenschrift, 1989, 67, 818-825.	0.6	68
13	Megakaryocyte precursors (pro-and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. Vigiliae Christianae, 1989, 58, 295-302.	0.1	14
14	Impaired interleukin-2 production by t-lymphocytes in polycythemia vera. Journal of Clinical Laboratory Analysis, 1989, 3, 84-87.	0.9	4
15	Polycythemia vera. A clinical study of 141 patients. Blut, 1989, 59, 493-500.	1.2	39
16	Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis. Klinische Wochenschrift, 1990, 68, 18-25.	0.6	21
17	Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40. Blut, 1990, 60, 233-237.	1.2	29
18	Leukemic transformation in polycythemia vera: Analysis of risk factors. American Journal of Hematology, 1990, 34, 32-36.	2.0	70
19	Clinical course of essential thrombocythemia in 147 cases. Cancer, 1990, 66, 549-556.	2.0	291
20	Hematologic disorders and ischemic stroke. A selective review.. Stroke, 1990, 21, 1111-1121.	1.0	218

#	ARTICLE	IF	CITATIONS
21	Antineoplastic Drugs in 1990. <i>Drugs</i> , 1990, 39, 652-673.	4.9	38
22	Chromosome Studies in 104 Patients With Polycythemia Vera. <i>Mayo Clinic Proceedings</i> , 1991, 66, 287-299.	1.4	138
23	Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, S58-S63.	0.9	10
24	Relief of itch associated with myeloproliferative disease by alpha-interferon. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 81-81.	0.5	0
25	Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure. <i>American Journal of Hematology</i> , 1991, 37, 141-142.	2.0	4
26	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. <i>Cancer</i> , 1991, 68, 2310-2318.	2.0	33
27	Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. <i>Annals of Hematology</i> , 1991, 63, 101-106.	0.8	112
28	Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 6848-6852.	3.3	246
29	Polycythaemia Vera Following Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1992, 8, 501-502.	0.6	4
30	High Incidence of Myeloproliferative Disorders in Ashkenazi Jews in Northern Israel. <i>Leukemia and Lymphoma</i> , 1992, 7, 251-255.	0.6	58
31	Clinical Aspects of Chronic Myeloproliferative Diseases. <i>American Journal of the Medical Sciences</i> , 1992, 304, 109-124.	0.4	3
32	Cardiac involvement in patients with myeloproliferative disorders. <i>American Journal of Medicine</i> , 1992, 93, 498-504.	0.6	65
33	Polycythemia vera. <i>Disease-a-Month</i> , 1992, 38, 158-212.	0.4	14
34	Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. <i>American Journal of Hematology</i> , 1992, 40, 283-289.	2.0	23
35	Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. <i>American Journal of Hematology</i> , 1993, 43, 316-318.	2.0	57
36	Recombinant interferon $\alpha$ -2b in the treatment of polycythemia vera. <i>American Journal of Hematology</i> , 1993, 44, 155-157.	2.0	30
37	Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler. <i>Journal of Internal Medicine</i> , 1993, 234, 599-602.	2.7	16
38	Risk of stroke in adults with cyanotic congenital heart disease.. <i>Circulation</i> , 1993, 87, 1954-1959.	1.6	156

#	ARTICLE	IF	CITATIONS
39	Thromboembolic complications of polycythemia: Polycythemia vera versus smokers' polycythemia. <i>Journal of Vascular Surgery</i> , 1993, 17, 518-523.	0.6	27
40	Portal Hypertension as Presenting Feature of a Myeloproliferative Disorder: Diagnosis and Therapeutic Dilemmas. <i>Scandinavian Journal of Gastroenterology</i> , 1993, 28, 74-79.	0.6	15
41	Case 31-1993. <i>New England Journal of Medicine</i> , 1993, 329, 417-423.	13.9	1
42	The Hypercoagulability of Polycythemia Vera. <i>Hospital Practice (1995)</i> , 1993, 28, 65-73.	0.5	6
43	A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. <i>Annals of Hematology</i> , 1994, 68, 247-250.	0.8	43
44	Improvement of sickle cell anemia by iron-limited erythropoiesis. <i>American Journal of Hematology</i> , 1994, 47, 74-81.	2.0	40
45	Trends in the incidence of polycythemia vera among olmsted county, Minnesota residents, 1935â€“1989. <i>American Journal of Hematology</i> , 1994, 47, 89-93.	2.0	109
46	Polycythemia vera complicated by squamous cell carcinoma of the esophagus. <i>American Journal of Hematology</i> , 1994, 47, 148-149.	2.0	0
47	Pulmonary hypertension in polycythemia vera. <i>American Journal of Hematology</i> , 1994, 47, 242-244.	2.0	34
48	The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. <i>British Journal of Haematology</i> , 1994, 86, 233-235.	1.2	73
49	Occurrence, etiology, and clinical significance of extreme thrombocytosis: A study of 280 cases. <i>American Journal of Medicine</i> , 1994, 96, 247-253.	0.6	207
50	Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1994, 331, 1630-1641.	13.9	332
51	Posttransplant Erythrocytosis: An Enigma Revisited. <i>American Journal of Kidney Diseases</i> , 1994, 24, 1-11.	2.1	122
52	Henoch-Schoenlein Purpura Nephritis Associated with Polycythemia Vera.. <i>Internal Medicine</i> , 1994, 33, 36-40.	0.3	9
53	Primary Polycythaemia Vera in Elderly. <i>Journal of International Medical Research</i> , 1994, 22, 121-129.	0.4	3
54	Long-term treatment with interferon- $\alpha$ 2b for severe pruritus in patients with polycythaemia vera. <i>British Journal of Haematology</i> , 1995, 89, 313-318.	1.2	62
55	Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. <i>Clinical Endocrinology</i> , 1995, 43, 167-174.	1.2	4
56	Role of interferon alpha-2a in the treatment of polycythemia vera. <i>American Journal of Hematology</i> , 1995, 48, 55-57.	2.0	19

#	ARTICLE	IF	CITATIONS
57	Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. <i>Cancer</i> , 1995, 75, 471-477.	2.0	40
58	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 20, 203-222.	2.0	74
59	An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis. <i>Annals of Hematology</i> , 1995, 70, 279-280.	0.8	13
60	Anaplastic B-Cell (Ki-1) Lymphoma Developing in a Patient with Polycythemia Vera. <i>Leukemia and Lymphoma</i> , 1995, 19, 507-509.	0.6	5
61	Common Thrombotic Disorders Defined by CBC Platelet Parameters. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1995, 1, 188-201.	0.7	4
62	Outcome Analysis for Treatment in 100 Patients with Deep Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1995, 1, 39-48.	0.7	1
63	Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. <i>American Journal of Hematology</i> , 1996, 52, 14-20.	2.0	60
64	Polycythemia vera. <i>Seminars in Oncology Nursing</i> , 1996, 12, 70-77.	0.7	1
65	UVB phototherapy for pruritus in polycythaemia vera. <i>Journal of Dermatological Treatment</i> , 1996, 7, 245-246.	1.1	8
66	Polycythemia Vera Associated with Metastatic Carcinoid. <i>Cancer Investigation</i> , 1996, 14, 120-123.	0.6	3
67	Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 1996, 52, 42-46.		96
68	Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty. <i>Annals of Hematology</i> , 1996, 72, 89-91.	0.8	10
69	Aspirin in Polycythemia Vera and Essential Thrombocythemia: Current Facts and Perspectives. <i>Leukemia and Lymphoma</i> , 1996, 22, 83-86.	0.6	11
70	Investigation of patients with polycythaemia. <i>Postgraduate Medical Journal</i> , 1996, 72, 519-524.	0.9	4
71	Diagnostic and Differential Criteria of Essential Thrombocythemia and Reactive Thrombocytosis. <i>Leukemia and Lymphoma</i> , 1996, 22, 41-45.	0.6	65
72	Clinical and Hematological Response to Hydroxyurea in a Patient with Hb Leporbp-Thalassemia. <i>Hemoglobin</i> , 1997, 21, 219-226.	0.4	29
73	Myoclonus Due to Chlorambucil in Two Adults with Lymphoma. <i>Annals of Pharmacotherapy</i> , 1997, 31, 171-174.	0.9	25
74	Inapparent Polycythemia Vera: An Unrecognized Diagnosis. <i>American Journal of Medicine</i> , 1997, 102, 14-20.	0.6	74

#	ARTICLE	IF	CITATIONS
75	Polycythemia vera in Chinese patients: Thirty-six years of experience. , 1997, 56, 59-62.		7
76	Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone. , 1997, 56, 126-128.		32
77	Platelet transfusion for surgery in the presence of polycythemia vera. Acta Anaesthesiologica Scandinavica, 1998, 42, 270-271.	0.7	2
78	Long term treatment of myeloproliferative disease with interferon- $\alpha$ 2b. Cancer, 1998, 83, 1205-1213.	2.0	98
79	A novel thrombopoietin signaling defect in polycythemia vera platelets. Stem Cells, 1998, 16, 185-192.	1.4	29
80	Primary Erythrocytosis in a 24-Year-Old Arabian Gelding. Journal of Veterinary Internal Medicine, 1998, 12, 384-388.	0.6	17
81	Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera. New England Journal of Medicine, 1998, 338, 572-580.	13.9	297
82	Therapeutic Efficacy of Recombinant Interferon-Alpha in Polycythaemia vera. Acta Haematologica, 1998, 99, 89-91.	0.7	5
83	Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency?. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 441-458.	0.6	20
84	Role of Human Leukocyte Interferon- $\alpha$ in the Treatment of Patients With Polycythemia Vera. American Journal of the Medical Sciences, 1998, 315, 237-241.	0.4	8
85	Survival in a Patient with Polycythaemia Vera for over Thirty Years: Implications for Treatment Decisions in Younger Patients. Leukemia and Lymphoma, 1998, 32, 195-198.	0.6	3
87	Posttranslational Processing of the Thrombopoietin Receptor Is Impaired in Polycythemia Vera. Blood, 1999, 94, 2555-2561.	0.6	107
88	Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. British Journal of Haematology, 1999, 105, 618-625.	1.2	45
89	Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. , 1999, 60, 130-135.		77
90	Thrombotic Pulmonary Arteriopathy in Polycythemia vera. Pathology Research and Practice, 1999, 195, 653-656.	1.0	4
91	Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. American Journal of Kidney Diseases, 1999, 34, 889-893.	2.1	51
92	Cerebral embolism in a patient with polycythemia rubra vera. European Journal of Neurology, 2000, 7, 87-90.	1.7	16
93	Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. British Journal of Haematology, 2000, 110, 116-124.	1.2	100

#	ARTICLE	IF	CITATIONS
94	Systemic radiation therapy with unsealed radionuclides. <i>Seminars in Radiation Oncology</i> , 2000, 10, 94-102.	1.0	13
95	Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. <i>Blood</i> , 2000, 95, 2569-2576.	0.6	189
96	Acquired DNA mutations associated with in vivo hydroxyurea exposure. <i>Blood</i> , 2000, 95, 3589-3593.	0.6	114
97	Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG. <i>Leukemia and Lymphoma</i> , 2000, 36, 239-253.	0.6	78
98	Simultaneous occurrence of multiple aetiologies of polycythaemia: renal cell carcinoma, sleep apnoea syndrome, and relative polycythaemia in a smoker with masked polycythaemia rubra vera. <i>Journal of Clinical Pathology</i> , 2000, 53, 561-564.	1.0	3
99	Should Whole-Body Red Cell Mass Be Measured or Calculated?. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 25-31.	0.6	22
100	Polycythaemia Vera and Essential Thrombocythaemia in the Elderly. <i>Drugs and Aging</i> , 2000, 17, 107-119.	1.3	5
101	Plasma Erythropoietin Concentrations in Polycythaemia Vera with Special Reference to Myelosuppressive Therapy. <i>Leukemia and Lymphoma</i> , 2000, 37, 189-195.	0.6	13
102	Clinical evaluation of hypercoagulable states. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 57-70.	1.0	2
103	Alterations of the insulin-like growth factor system in patients with polycythemia vera. <i>Molecular and Cellular Endocrinology</i> , 2001, 181, 189-197.	1.6	13
104	Long-term use of anagrelide in young patients with essential thrombocythemia. <i>Blood</i> , 2001, 97, 863-866.	0.6	154
105	Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. <i>British Journal of Haematology</i> , 2001, 112, 392-396.	1.2	33
106	Idiopathic erythrocytosis - a declining entity. <i>British Journal of Haematology</i> , 2001, 115, 774-781.	1.2	19
107	Acquired thrombophilic syndromes. <i>Blood Reviews</i> , 2001, 15, 31-48.	2.8	13
108	Polycythemia rubra vera versus Secondary Polycythemias. A Clinicopathological Evaluation of Distinctive Features in 199 Patients. <i>Pathology Research and Practice</i> , 2001, 197, 77-84.	1.0	48
109	Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. <i>European Journal of Haematology</i> , 2001, 66, 143-151.	1.1	115
110	Options for Radionuclide Therapy: From Fixed Activity to Patient-Specific Treatment Planning. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 71-82.	0.7	26
111	Red Cell Mass, Spleen Size and Plasma Erythropoietin in Polycythaemia vera and Apparent Polycythaemia. <i>Acta Haematologica</i> , 2002, 108, 1-7.	0.7	7

#	ARTICLE	IF	CITATIONS
112	Current Management of Polycythemia Vera. <i>Leukemia and Lymphoma</i> , 2002, 43, 1-7.	0.6	11
113	The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. <i>Blood</i> , 2002, 99, 1144-1149.	0.6	116
114	Polycythemia vera: myths, mechanisms, and management. <i>Blood</i> , 2002, 100, 4272-4290.	0.6	404
115	Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. <i>Blood</i> , 2002, 100, 2441-2448.	0.6	61
116	Neurologic Manifestations of Hematologic Disorders. <i>Neurologic Clinics</i> , 2002, 20, 265-281.	0.8	20
117	Peripheral blood findings in chronic myeloproliferative disorders. <i>Clinics in Laboratory Medicine</i> , 2002, 22, 137-151.	0.7	1
118	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. <i>European Journal of Haematology</i> , 2002, 69, 43-49.	1.1	11
119	Onset of oral extranodal large B-cell non-Hodgkin's lymphoma in a patient with polycythemia vera: a rare presentation. <i>Oral Oncology</i> , 2002, 38, 624-626.	0.8	5
120	Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. <i>American Journal of Hematology</i> , 2002, 69, 185-191.	2.0	36
121	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2002, 71, 1-6.	2.0	78
122	Clinical and Pathological Criteria for the Diagnosis of Essential Thrombocythemia, Polycythemia Vera, and Idiopathic Myelofibrosis (Agnogenic Myeloid Metaplasia). <i>International Journal of Hematology</i> , 2002, 76, 133-145.	0.7	120
123	Treatment of polycythemia vera with recombinant interferon. <i>International Journal of Hematology</i> , 2002, 76, 294-295.	0.7	3
124	What is the standard treatment in essential thrombocythemia. <i>International Journal of Hematology</i> , 2002, 76, 311-317.	0.7	6
125	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. <i>British Journal of Haematology</i> , 2002, 116, 855-861.	1.2	36
126	Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. <i>British Journal of Dermatology</i> , 2002, 147, 979-981.	1.4	74
127	THE OPTIMAL MANAGEMENT OF POLYCYTHAEMIA VERA. <i>British Journal of Haematology</i> , 2002, 116, 243-254.	1.2	39
128	Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. <i>British Journal of Haematology</i> , 2002, 118, 786-790.	1.2	135
129	Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected*. <i>British Journal of Haematology</i> , 2002, 119, 558-566.	1.2	85



#	ARTICLE	IF	CITATIONS
130	Use and risks of phosphorus-32 in the treatment of polycythaemia vera. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1413-1417.	3.3	11
131	Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. <i>European Journal of Haematology</i> , 2003, 71, 377-384.	1.1	17
132	Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. <i>European Journal of Haematology</i> , 2003, 71, 276-282.	1.1	9
133	Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera. <i>Experimental Hematology</i> , 2003, 31, 118-121.	0.2	4
134	Karyotypic abnormalities in myelofibrosis following polycythemia vera. <i>Cancer Genetics and Cytogenetics</i> , 2003, 140, 118-123.	1.0	54
135	Reply to McMullin et al. <i>British Journal of Haematology</i> , 2003, 120, 544-545.	1.2	1
136	Polycythemia Vera: A Comprehensive Review and Clinical Recommendations. <i>Mayo Clinic Proceedings</i> , 2003, 78, 174-194.	1.4	137
137	Polycythemia vera. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1191-1210.	0.9	8
138	Chronic Myeloproliferative Disorders. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 200-224.	0.9	101
139	Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients. <i>Thrombosis Research</i> , 2003, 112, 229-232.	0.8	25
140	Modern treatment strategies in polycythemia vera. <i>Seminars in Hematology</i> , 2003, 40, 26-29.	1.8	16
141	Hypercoagulable state testing and malignancy screening following venous thromboembolic events. <i>Vascular Medicine</i> , 2003, 8, 33-46.	0.8	16
142	Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman. <i>Leukemia and Lymphoma</i> , 2003, 44, 1483-1488.	0.6	8
143	Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. <i>Blood</i> , 2003, 102, 3793-3796.	0.6	116
144	Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11444-11447.	3.3	125
145	Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. <i>Journal of Internal Medicine</i> , 2004, 256, 161-165.	2.7	59
146	Markers of Endothelial and In Vivo Platelet Activation in Patients with Essential Thrombocythemia and Polycythemia Vera. <i>International Journal of Hematology</i> , 2004, 79, 253-259.	0.7	28
147	Review. <i>Platelets</i> , 2004, 15, 67-84.	1.1	81

#	ARTICLE	IF	CITATIONS
148	A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). <i>Pathologie Et Biologie</i> , 2004, 52, 285-288.	2.2	61
149	Risk of leukemic transformation in PV and ET patients. <i>Pathologie Et Biologie</i> , 2004, 52, 289-293.	2.2	8
150	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. <i>American Journal of Medicine</i> , 2004, 117, 755-761.	0.6	415
151	The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?. <i>Seminars in Hematology</i> , 2004, 41, 15-17.	1.8	42
152	Treatment paradigms in the management of myeloproliferative disorders. <i>Seminars in Hematology</i> , 2004, 41, 18-22.	1.8	22
154	Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. <i>Leukemia Research</i> , 2005, 29, 481-491.	0.4	89
155	Risk-adapted therapy in essential thrombocythemia and polycythemia vera. <i>Blood Reviews</i> , 2005, 19, 243-252.	2.8	73
156	Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2005, 128, 275-290.	1.2	427
157	An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. <i>British Journal of Haematology</i> , 2005, 129, 701-705.	1.2	95
158	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. <i>British Journal of Haematology</i> , 2005, 130, 174-195.	1.2	314
159	Transition of polycythemia vera to chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 75, 264-266.	1.1	10
160	Interferon $\alpha$ therapy for patients with essential thrombocythemia. <i>Cancer</i> , 2005, 103, 2551-2557.	2.0	21
161	Leukemic transformation of polycythemia vera. <i>Cancer</i> , 2005, 104, 1032-1036.	2.0	79
162	Eosinophilic Leukemic Transformation in Polycythemia Rubra Vera (PRV). <i>Leukemia and Lymphoma</i> , 2005, 46, 447-450.	0.6	4
163	SDF1-3'UTR Gene Polymorphism Is Associated with Chronic Myeloproliferative Disease and Thrombotic Events. <i>Clinical Chemistry</i> , 2005, 51, 2411-2414.	1.5	14
164	Clinical Trials in Myeloproliferative Disorders: Looking Forward. <i>Seminars in Hematology</i> , 2005, 42, 259-265.	1.8	9
166	Polycythemia Vera: Scientific Advances and Current Practice. <i>Seminars in Hematology</i> , 2005, 42, 206-220.	1.8	72
167	Current Treatment Approaches of Polycythemia Vera. <i>Clinical Leukemia</i> , 2006, 1, 41-45.	0.2	1

#	ARTICLE	IF	CITATIONS
168	Evidence-based management of polycythemia vera. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 483-493.	0.7	15
169	Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. <i>Platelets</i> , 2006, 17, 528-544.	1.1	99
170	Recovery of splenic infarction with anti-platelet treatments and platelet-apheresis in polycythemia vera. <i>Transfusion and Apheresis Science</i> , 2006, 34, 199-202.	0.5	5
171	Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. <i>Blood</i> , 2006, 108, 3913-3915.	0.6	104
172	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. <i>Cancer</i> , 2006, 107, 2206-2211.	2.0	82
173	Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. <i>American Journal of Hematology</i> , 2006, 81, 676-683.	2.0	17
174	How I treat patients with polycythemia vera. <i>Blood</i> , 2007, 109, 5104-5111.	0.6	120
175	Delayed Manifestation and Slow Progression of Cerebral Infarction Caused by Polycythemia Rubra Vera. <i>American Journal of the Medical Sciences</i> , 2007, 333, 317-320.	0.4	7
176	JAK2 V617F: implications for thrombosis in myeloproliferative diseases. <i>Current Opinion in Hematology</i> , 2007, 14, 450-454.	1.2	24
177	Reduced diversity of the human erythrocyte membrane sialic acids in polycythemia vera. Absence of N-glycolylneuraminic acid and characterisation of N-acetylneuraminic acid 1,7 lactone. <i>Biochimie</i> , 2007, 89, 355-359.	1.3	24
178	Clinical update: cyanotic adult congenital heart disease. <i>Lancet, The</i> , 2007, 370, 1530-1532.	6.3	77
179	The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). <i>Cancer</i> , 2007, 109, 68-76.	2.0	356
180	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. <i>British Journal of Haematology</i> , 2007, 138, 354-358.	1.2	139
181	Phenotypic variations and new mutations in JAK2 V617F in "negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. <i>Experimental Hematology</i> , 2007, 35, 1641-1646.	0.2	89
182	Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2V617F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. <i>Experimental Hematology</i> , 2007, 35, 1668-1676.	0.2	43
183	Unanswered questions in polycythaemia vera. <i>European Journal of Haematology</i> , 2007, 79, 18-21.	1.1	0
184	Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 43-46.	1.2	2
185	Cyanotic Congenital Heart Disease (CCHD) with Symptomatic Erythrocytosis. <i>Journal of General Internal Medicine</i> , 2007, 22, 1775-1777.	1.3	28

#	ARTICLE	IF	CITATIONS
186	The treatment of polycythaemia vera: an update in the JAK2 era. <i>Internal and Emergency Medicine</i> , 2007, 2, 13-18.	1.0	15
187	Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China. <i>International Journal of Hematology</i> , 2008, 88, 530-535.	0.7	12
188	Phase II open label trial of imatinib in polycythemia rubra vera. <i>International Journal of Hematology</i> , 2008, 88, 489-494.	0.7	6
189	Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. <i>Leukemia</i> , 2008, 22, 1494-1502.	3.3	102
190	Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. <i>Leukemia</i> , 2008, 22, 905-914.	3.3	175
191	The <i>JAK2</i> <sup>V617F</sup> mutation and thrombosis. <i>British Journal of Haematology</i> , 2008, 143, 307-320.	1.2	69
192	Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. <i>British Journal of Haematology</i> , 1987, 67, 285-291.	1.2	5
193	Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens. <i>Experimental Hematology</i> , 2008, 36, 1480-1486.e2.	0.2	78
194	The effect of hydroxyurea in spinal muscular atrophy cells and patients. <i>Journal of the Neurological Sciences</i> , 2008, 268, 87-94.	0.3	55
195	Thrombotic complications of polycythemia vera. <i>Hematology</i> , 2008, 13, 319-323.	0.7	7
196	Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. <i>Blood</i> , 2008, 111, 60-70.	0.6	229
197	A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. <i>Blood</i> , 2008, 111, 3383-3387.	0.6	108
198	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. <i>Blood</i> , 2008, 112, 1085-1090.	0.6	29
200	Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution. <i>Sao Paulo Medical Journal</i> , 2008, 126, 52-57.	0.4	4
201	Hyperviscosity and stroke. , 0, , 347-356.		3
202	Perspective: Osler's 1903 Paper on Polycythemia Vera. <i>American Journal of the Medical Sciences</i> , 2008, 335, 418-419.	0.4	3
203	Hemostatic Disorders Presenting as Cerebral Infarction. , 2009, , 173-195.		0
204	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2068-2073.	1.1	100

#	ARTICLE	IF	CITATIONS
205	Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. <i>Hematology</i> , 2009, 14, 1-10.	0.7	4
206	Hydroxyurea Treatment of Myeloproliferative Disorders. <i>Acta Medica Scandinavica</i> , 1987, 222, 169-174.	0.0	11
207	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1437-1450.	1.6	23
208	Hb Linköping (H <sup>2</sup> 36 Pro → Thr): A new high oxygen affinity hemoglobin variant found in two families of Finnish origin. <i>European Journal of Haematology</i> , 1987, 39, 452-456.	1.1	6
209	Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*. <i>European Journal of Haematology</i> , 2009, 41, 375-381.	1.1	146
210	Reversal of myelofibrosis by hydroxyurea. <i>European Journal of Haematology</i> , 1990, 44, 33-38.	1.1	89
211	The management of thrombocytosis. <i>European Journal of Haematology</i> , 1990, 44, 81-88.	1.1	38
212	Incidence of polycythemia vera in a defined population. <i>European Journal of Haematology</i> , 1992, 48, 20-26.	1.1	48
213	Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. <i>European Journal of Haematology</i> , 1994, 52, 134-139.	1.1	148
215	Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. <i>European Journal of Haematology</i> , 1996, 56, 287-292.	1.1	16
216	Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. <i>European Journal of Haematology</i> , 1996, 56, 158-162.	1.1	16
217	Increase of CD34 positive cells in polycythaemia vera. <i>European Journal of Haematology</i> , 1997, 59, 171-176.	1.1	15
218	Long-term therapeutic efficacy and toxicity of recombinant interferon-α 2a in polycythaemia vera. <i>European Journal of Haematology</i> , 1998, 60, 273-277.	1.1	18
219	The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. <i>European Journal of Haematology</i> , 1999, 62, 27-31.	1.1	26
220	The red cell mass, plasma erythropoietin and spleen size in apparent polycythaemia. <i>European Journal of Haematology</i> , 1999, 62, 43-48.	1.1	13
221	New and old prognostic factors in polycythemia vera. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 19-24.	1.2	3
222	Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. <i>Leukemia Research</i> , 2009, 33, 11-18.	0.4	40
223	Treatment options for essential thrombocythemia and polycythemia vera. <i>Expert Review of Hematology</i> , 2009, 2, 41-55.	1.0	6

#	ARTICLE	IF	CITATIONS
224	Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. <i>Haematologica</i> , 2010, 95, 1090-1097.	1.7	79
225	Myeloproliferative Neoplasms: New Translational Therapies. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 667-683.	1.9	7
226	Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. <i>Histopathology</i> , 2010, 56, 758-767.	1.6	64
227	Guideline for investigation and management of adults and children presenting with a thrombocytosis. <i>British Journal of Haematology</i> , 2010, 149, 352-375.	1.2	253
228	JAK2 V617F and the evolving paradigm of polycythemia vera. <i>The Korean Journal of Hematology</i> , 2010, 45, 90.	0.7	3
229	Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia. <i>Case Reports in Neurology</i> , 2010, 2, 150-156.	0.3	16
230	Detection of Exon 12 Mutations in the JAK2 Gene. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 278-282.	1.2	17
231	The prevalence and risk factors for cholelithiasis and asymptomatic gallstones in adults with congenital heart disease. <i>International Journal of Cardiology</i> , 2011, 152, 171-176.	0.8	23
232	Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. <i>Thrombosis</i> , 2011, 2011, 1-8.	1.4	42
233	Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies. <i>Thrombosis</i> , 2011, 2011, 1-16.	1.4	85
234	The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. <i>Thrombosis</i> , 2011, 2011, 1-9.	1.4	53
235	Polycythemia rubra vera: An unlikely cause of severe pulmonary embolism. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2011, 24, 51-53.	0.1	1
236	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. <i>Haematologica</i> , 2011, 96, 454-458.	1.7	65
237	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 367-374.	1.7	67
238	The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2011, 86, 148-155.	1.1	59
240	Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , 2011, 39, 95-101.	0.2	34
241	Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2011, 86, 974-979.	2.0	37
242	The management of Eisenmenger syndrome in the modern treatment era: a case report. <i>European Respiratory Review</i> , 2011, 20, 293-296.	3.0	8

#	ARTICLE	IF	CITATIONS
243	Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980. <i>Journal of Clinical Oncology</i> , 2011, 29, 3907-3913.	0.8	223
244	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocythemia and post-polycythemia vera myelofibrosis, but not essential thrombocythemia or polycythemia vera: analysis of molecular genetics and clinical phenotypes. <i>Haematologica</i> , 2011, 96, 1462-1469.	1.7	83
245	<i>BCR-ABL1</i> -negative chronic myeloid neoplasms: an update on management techniques. <i>Future Oncology</i> , 2012, 8, 575-593.	1.1	4
247	A prognostic model to predict survival in 867 World Health Organizationâ€‘defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201.	0.6	222
248	A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228.	0.6	37
249	How I treat polycythemia vera. <i>Blood</i> , 2012, 120, 275-284.	0.6	74
250	JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. <i>Blood</i> , 2012, 119, 2721-2730.	0.6	151
251	Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. <i>Blood</i> , 2012, 119, 2219-2227.	0.6	78
252	Myeloproliferative Neoplasms. <i>Disease-a-Month</i> , 2012, 58, 177-194.	0.4	7
253	Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 170-176.	0.6	43
254	Front-line therapy in polycythemia vera and essential thrombocythemia. <i>Blood Reviews</i> , 2012, 26, 205-211.	2.8	56
255	Clinical Predictors of Outcome in MPN. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1101-1116.	0.9	5
256	Thrombotic disease in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 571-581.	0.9	102
257	How to manage children and young adults with myeloproliferative neoplasms. <i>Leukemia</i> , 2012, 26, 1452-1457.	3.3	34
258	Thrombus in Right Ventricular Outflow Tract: Unique Cause of Refractory Cyanotic Spell. <i>Congenital Heart Disease</i> , 2012, 7, E56-E58.	0.0	0
259	Treatment of polycythemia vera with imatinib mesylate. <i>Leukemia Research</i> , 2012, 36, 156-162.	0.4	21
260	Leukaemic transformation of Philadelphia chromosomeâ€‘negative myeloproliferative neoplasms: are Asian patients different?. <i>Internal Medicine Journal</i> , 2012, 42, 513-517.	0.5	1
261	Prevalence of Venous Thromboembolism in Patients With Secondary Polycythemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 363-366.	0.7	33

#	ARTICLE	IF	CITATIONS
262	Pharmacotherapy of polycythemia vera. Expert Opinion on Orphan Drugs, 2013, 1, 977-985.	0.5	0
263	The Pathogenesis, Diagnosis, and Treatment of Polycythaemia Vera. , 2013, , 135-153.		0
264	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells, Molecules, and Diseases, 2013, 50, 190-195.	0.6	21
265	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology, 2013, 6, 49-58.	1.0	96
266	Bleeding and Thrombosis in Hematologic Neoplasia. , 2013, , 1363-1385.		1
267	Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. Journal of Thrombosis and Haemostasis, 2013, 11, 1215-1227.	1.9	67
268	Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 374-381.	0.7	7
269	Treatment options for myelofibrosis and myeloproliferative neoplasia. International Journal of Hematologic Oncology, 2013, 2, 487-495.	0.7	1
270	Paraspinal and Presacral Extramedullary Hematopoiesis: A Rare Manifestation of Polycythemia Vera. Iranian Journal of Radiology, 2013, 10, 164-168.	0.1	4
271	Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?. Blood Coagulation and Fibrinolysis, 2013, 24, 311-316.	0.5	22
272	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leukemia and Lymphoma, 2013, 54, 1989-1995.	0.6	65
273	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica, 2013, 98, e135-e137.	1.7	33
274	Rethinking the diagnostic criteria of polycythemia vera. Leukemia, 2014, 28, 1191-1195.	3.3	52
275	Chronic myeloproliferative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 1073-1081.	1.0	11
276	Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. American Journal of Hematology, 2014, 89, 438-442.	2.0	9
278	Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?. Best Practice and Research in Clinical Haematology, 2014, 27, 141-153.	0.7	40
279	Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica, 2014, 99, 945-949.	1.7	24
280	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. American Journal of Hematology, 2015, 90, 434-437.	2.0	19



#	ARTICLE	IF	CITATIONS
281	The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. <i>Thrombosis Research</i> , 2015, 135, 272-280.	0.8	61
282	Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1185-1194.	0.9	7
283	New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. <i>American Journal of Hematology</i> , 2015, 90, 683-685.	2.0	18
284	Current and future treatment options for polycythemia vera. <i>Annals of Hematology</i> , 2015, 94, 901-910.	0.8	47
285	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 715-727.	0.2	7
286	New Therapeutic Approaches in Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S27-S33.	0.2	11
287	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. <i>Journal of Clinical Oncology</i> , 2015, 33, 3953-3960.	0.8	69
288	Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1283-1293.	1.4	38
289	Target hematologic values in the management of essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2015, 94, 4-11.	1.1	16
290	Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 205-215.	0.7	6
291	β-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm. <i>Medicine (United States)</i> , 2016, 95, e3355.	0.4	5
292	Myeloproliferative neoplasms: A decade of discoveries and treatment advances. <i>American Journal of Hematology</i> , 2016, 91, 50-58.	2.0	150
293	Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 589-592.	0.2	0
294	Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2016, 6, e427-e427.	2.8	21
295	Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. <i>Haematologica</i> , 2017, 102, e166-e169.	1.7	14
296	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. <i>Haematologica</i> , 2017, 102, e219-e221.	1.7	21
298	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. <i>Haematologica</i> , 2017, 102, 18-29.	1.7	16
299	A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. <i>American Journal of Hematology</i> , 2017, 92, 1131-1136.	2.0	57

#	ARTICLE	IF	CITATIONS
300	After 10 years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. <i>Blood Reviews</i> , 2017, 31, 101-118.	2.8	16
302	Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. <i>Blood Cancer Journal</i> , 2018, 8, 5.	2.8	20
303	Bleeding and Thrombosis in Hematologic Neoplasia. , 2018, , 1263-1289.		1
304	Hematologic Follow-up as Clue to Polycythemia Vera due to <scp>JAK</scp>2 Mutation Presenting as Late Onset Chorea. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 83-85.	0.8	4
305	The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. <i>Blood Advances</i> , 2018, 2, 2681-2690.	2.5	13
306	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. <i>Leukemia</i> , 2018, 32, 2077-2081.	3.3	30
307	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	1.1	11
308	Therapy-Related Acute Myelogenous Leukemia. , 2018, , 465-482.		0
309	Dysregulated iron metabolism in polycythemia vera: etiology and consequences. <i>Leukemia</i> , 2018, 32, 2105-2116.	3.3	84
310	University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). <i>Clinical Trials</i> , 2018, 15, 366-385.	0.7	0
311	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
312	How I treat polycythemia vera. <i>Blood</i> , 2019, 134, 341-352.	0.6	54
313	Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. <i>Haematologica</i> , 2019, 104, 653-658.	1.7	40
314	Myeloproliferative neoplasms. , 2020, , 555-588.		0
315	Thrombocytosis and Thrombosis: Is There Really a Correlation?. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 261-267.	1.2	14
316	An agenda for future research projects in polycythemia vera and essential thrombocythemia. <i>Haematologica</i> , 2020, 105, 1999-2003.	1.7	6
317	Prognostic models in the myeloproliferative neoplasms. <i>Blood Reviews</i> , 2020, 42, 100713.	2.8	10
318	Current management strategies for polycythemia vera and essential thrombocythemia. <i>Blood Reviews</i> , 2020, 42, 100714.	2.8	35

#	ARTICLE	IF	CITATIONS
319	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. <i>Blood Advances</i> , 2020, 4, 2567-2576.	2.5	37
320	Is there a gender effect in polycythemia vera?. <i>Annals of Hematology</i> , 2021, 100, 11-25.	0.8	9
321	Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia. <i>Frontiers in Oncology</i> , 2020, 10, 636675.	1.3	5
322	Polycythemia Vera (PV): Update on Emerging Treatment Options. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 209-221.	0.9	9
323	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT JOverlock 10 Tf 50	2.2	79
324	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. <i>Leukemia</i> , 2021, 35, 3339-3351.	3.3	57
325	Management of Free-Floating Thrombus in the Vertebral Artery in a Middle-Aged Smoker with Secondary Polycythemia Vera. <i>International Medical Case Reports Journal</i> , 2021, Volume 14, 663-668.	0.3	0
326	RBC distribution width predicts thrombosis risk in polycythemia vera. <i>Leukemia</i> , 2022, 36, 566-568.	3.3	9
327	Thrombocytosis and thrombosis. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 383-388.	0.1	0
328	Interferon therapy of hematologic malignancies. <i>Cancer Treatment and Research</i> , 1998, 94, 1-21.	0.2	1
329	Oxygen affinity is decreased in patients with polycythaemia vera and essential thrombocythaemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2004, 64, 71-75.	0.6	3
330	Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. <i>British Journal of Haematology</i> , 1987, 67, 285-291.	1.2	60
331	A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 51-68.	0.9	3
332	A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 51-68.	0.9	7
333	Acquired DNA mutations associated with in vivo hydroxyurea exposure. <i>Blood</i> , 2000, 95, 3589-3593.	0.6	2
334	Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. <i>Blood</i> , 2000, 95, 2569-2576.	0.6	4
335	Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report. <i>Korean Journal of Anesthesiology</i> , 2015, 68, 608.	0.9	6
336	Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2016, 33, 187-195.	0.2	5

#	ARTICLE	IF	CITATIONS
337	Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 290-296.	0.7	2
338	Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia, 2022, 36, 569-572.	3.3	16
339	Bibliography Articles Cited in Commentaries. , 2000, , 1023-1058.		1
340	Influence of Obesity, Smoking and Alcohol Drinking on Hemoglobin Concentration.. Japanese Journal of MHTS, 2000, 27, 372-379.	0.0	0
341	Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen. , 2003, , 249-267.		0
342	Chronische myeloproliferative Erkrankungen. , 2003, , 1056-1069.		0
343	Myeloproliferative Disorders. , 2003, , 255-262.		0
345	Myeloproliferative Erkrankungen – Polycythaemia vera, idiopathische Myelofibrose, essentielle Thrombozythämie. , 2006, , 2749-2775.		0
346	Diseases of the Blood. , 2006, , 745-779.		0
347	Diseases of the Blood. , 2006, , 745-779.		0
348	Cyanotic Congenital Heart Disease: A Multisystem Disorder. , 2009, , 265-289.		5
349	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
350	Therapy of Polycythemia Vera and Essential Thrombocythemia. , 2011, , 97-115.		0
351	Myeloproliferative Neoplasms. , 2011, , 698-732.		2
352	Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options. , 2012, , 119-129.		0
353	First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia. , 2012, , 93-104.		0
354	Goal of Therapy and Monitoring the Response in Polycythemia Vera and Essential Thrombocythemia. , 2012, , 85-92.		0
355	Risk Classification. , 2012, , 71-84.		0

#	ARTICLE	IF	CITATIONS
356	Rezidivierende gastrointestinale Blutungen bei Pfortaderthrombose und antibiotikaresistente Pneumonie bei einem 38jÄhrigen Patienten. , 1988, , 705-709.		0
358	Zur Behandlung myeloproliferativer Syndrome mit Interferonen. , 1990, , 215-233.		3
359	Myeloproliferative Syndrome. , 1991, , 412-417.		0
360	Offene Radionuklide. , 1991, , 1112-1117.		0
361	Budd-Chiari Syndrome and Other Abdominal Thromboses in the Chronic Myeloproliferative Disorders. , 1993, , 295-298.		0
362	Myeloproliferative Syndrome. , 1995, , 567-579.		0
363	A case of polycythemia vera that accompanied with progressing ischemic stroke.. Nosotchu, 1996, 18, 65-69.	0.0	1
364	HÄmostasestÄrungen bei myeloproliferativen Erkrankungen. , 1996, , 23-36.		0
365	Role of Human Leukocyte Interferon-Î± in the Treatment of Patients With Polycythemia Vera. American Journal of the Medical Sciences, 1998, 315, 237-241.	0.4	7
366	Myeloproliferative Syndromes. , 1999, , 399-410.		0
367	Myeloproliferative Erkrankungen. , 1999, , 975-987.		0
368	Hypercoagulable Conditions Leading to Limb Ischemia. , 2017, , 267-278.		0
369	Chronische myeloproliferative Erkrankungen. , 2005, , 1108-1123.		0
372	Current applications of therapeutic phlebotomy. Blood Transfusion, 2014, 12 Suppl 1, s75-83.	0.3	18
373	Polycythemia vera-a climatological disease. Transactions of the American Clinical and Climatological Association, 1995, 106, 25-36; discussion 36-7.	0.9	0
374	A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis. Blood Transfusion, 2007, 5, 20-3.	0.3	19
375	Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable. American Health and Drug Benefits, 2014, 7, S36-47.	0.5	10
376	(32)P in the treatment of myeloproliferative disorders. Ulster Medical Journal, 2016, 85, 83-5.	0.2	2

#	ARTICLE	IF	CITATIONS
377	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer Journal, 2022, 12, 28.	2.8	31
378	Genetic Background of Polycythemia Vera. Genes, 2022, 13, 637.	1.0	6
379	An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis. Annals of Hematology, 1995, 70, 279-280.	0.8	1